[Myelodysplastic syndromes].
Garandeau C, Pautas E, Andreux M, Andreux J, Gaussem P, Siguret V.
Ann Biol Clin (Paris). 2000 Jul-Aug;58(4):405-16.
Refractory anemia with ringed sideroblasts and thrombocytosis without JAK2 V617F mutation: report of three cases.
Tatic A, Vasilică M, Coliţă A, Vasilache D, Dobrea C, Jardan C, Găman AM, Crişan AM, Coliţă D, Coriu D.
Rom J Morphol Embryol. 2013;54(4):1177-82.
Plasma proteome changes associated with refractory anemia and refractory anemia with ringed sideroblasts in patients with myelodysplastic syndrome.
Májek P, Riedelová-Reicheltová Z, Suttnar J, Pečánková K, Cermák J, Dyr JE.
Proteome Sci. 2013 Apr 8;11(1):14. doi: 10.1186/1477-5956-11-14.
JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
Schmitt-Graeff AH, Teo SS, Olschewski M, Schaub F, Haxelmans S, Kirn A, Reinecke P, Germing U, Skoda RC.
Haematologica. 2008 Jan;93(1):34-40. doi: 10.3324/haematol.11581.
[Myelodysplastic syndrome classification].
Ghariani I, Braham N, Hassine M, Kortas M.
Ann Biol Clin (Paris). 2013 Mar-Apr;71(2):139-44. doi: 10.1684/abc.2013.0804.
Identification of protein-coding and non-coding RNA expression profiles in CD34+ and in stromal cells in refractory anemia with ringed sideroblasts.
Baratti MO, Moreira YB, Traina F, Costa FF, Verjovski-Almeida S, Olalla-Saad ST.
BMC Med Genomics. 2010 Jul 15;3:30. doi: 10.1186/1755-8794-3-30.
Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
Rosati S, Mick R, Xu F, Stonys E, Le Beau MM, Larson R, Vardiman JW.
Leukemia. 1996 Jan;10(1):20-6.
Enhanced plasma protein carbonylation in patients with myelodysplastic syndromes.
Hlaváčková A, Štikarová J, Pimková K, Chrastinová L, Májek P, Kotlín R, Čermák J, Suttnar J, Dyr JE.
Free Radic Biol Med. 2017 Jul;108:1-7. doi: 10.1016/j.freeradbiomed.2017.03.007. Epub 2017 Mar 12.
Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes.
Germing U, Strupp C, Kuendgen A, Isa S, Knipp S, Hildebrandt B, Giagounidis A, Aul C, Gattermann N, Haas R.
Haematologica. 2006 Dec;91(12):1596-604.
Transfusion-dependent low-risk myelodysplastic patients receiving deferasirox: Long-term follow-up.
Improta S, Villa MR, Volpe A, Lombardi A, Stiuso P, Cantore N, Mastrullo L.
Oncol Lett. 2013 Dec;6(6):1774-1778. doi: 10.3892/ol.2013.1617. Epub 2013 Oct 10.
